cbdMD (YCBD) EBT Margin (2016 - 2026)

cbdMD (YCBD) posted EBT Margin of 5.64% for Q4 2025, up 60.82% sequentially from 14.4% in Q3 2025, and down 594.0% YoY from 1.14% in Q4 2024.

cbdMD (YCBD) EBT Margin (2016 - 2026) Analysis & Trends

cbdMD has reported EBT Margin for 10 years, with the latest figure at 5.64% in Q4 2025.

Quarterly EBT Margin fell 594.0% year-over-year to 5.64% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12.25% (up 142.0% YoY) and the FY2025 annual result came in at 10.63%, up 794.0% from the prior year.
EBT Margin advanced to 5.64% in Q4 2025 per YCBD's latest filing, from 14.4% in the prior quarter.
Over five years, EBT Margin peaked at 14.45% in Q2 2021 and troughed at 368.14% in Q2 2022.
A 5-year average of 72.75% and a median of 25.18% in 2023 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2023: EBT Margin plunged 38259 bps in 2022, then jumped 33921 bps in 2023.
Over 5 years, EBT Margin stood at 194.39% in 2021, then surged by 67 bps to 63.39% in 2022, then jumped by 71 bps to 18.54% in 2023, then surged by 102 bps to 0.3% in 2024, then tumbled by 2012 bps to 5.64% in 2025.
According to Business Quant data, EBT Margin over the past three periods registered 5.64%, 14.4%, and 19.43% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Haleon	44.36 Bn	43.40 Bn	-	-
2	Teva Pharmaceutical Industries	43.77 Bn	40.12 Bn	2.15 Bn	-10.99%
3	Zoetis	32.39 Bn	30.72 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.63 Bn	22.84 Bn	5.10 Bn	13.34%
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	47.58%
6	Viatris	18.94 Bn	18.06 Bn	1.46 Bn	-1.70%
7	Neurocrine Biosciences	15.63 Bn	15.24 Bn	935.80 Mn	16.91%
8	Elanco Animal Health	12.00 Bn	11.47 Bn	798.00 Mn	4.09%
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	cbdMD	5.37 Mn	3.26 Mn	3.04 Mn	-20.30%

Download Data